What’s the current market cap for Rigel Pharmaceuticals, Inc. stock?

Rigel Pharmaceuticals, Inc. (RIGL) has a market cap of $601m as of June 17, 2026.

What is the P/E ratio for Rigel Pharmaceuticals, Inc. stock?

The price to earnings (P/E) ratio for Rigel Pharmaceuticals, Inc. (RIGL) stock is 1.71 as of June 17, 2026.

Does Rigel Pharmaceuticals, Inc. stock pay dividends?

No, Rigel Pharmaceuticals, Inc. (RIGL) stock does not pay dividends to its shareholders as of June 17, 2026.

When is the next Rigel Pharmaceuticals, Inc. dividend payment date?

Rigel Pharmaceuticals, Inc. (RIGL) stock does not pay dividends to its shareholders.

What is the beta indicator for Rigel Pharmaceuticals, Inc.?

Rigel Pharmaceuticals, Inc. (RIGL) has a beta rating of 1.2. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Rigel Pharmaceuticals, Inc. stock | $RIGL Share Price

About Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.

Ticker

$RIGL

Sector

Health

Primary listing

NASDAQ

Employees

173

Headquarters

South San Francisco, United States

Website

www.rigel.com

RIGL Metrics

BasicAdvanced

$601m

1.71

$18.95

1.20

-

Bulls say / Bears say

Rigel posted 26% year-over-year growth in net product sales, reaching $54.9 million in Q1 2026, driven by TAVALISSE sales of $37.3 million (+31%), GAVRETO at $9.6 million (+7%), and REZLIDHIA at $8.0 million (+31%). (Reuters via Investing.com)

Rigel kept its full-year 2026 revenue guidance at $275 million to $290 million and expects to achieve net income profitability for the year, highlighting management’s confidence in commercial momentum. (Reuters via Investing.com)

TAVALISSE is sold under the name TAVLESSE in major European countries and in Japan, South Korea, Canada, and Israel via partnerships with Grifols, Kissei, and Medison, offering Rigel diversified international revenue streams. (Reuters via Investing.com)

Despite revenue growth, net income dropped 23.7% year-over-year to $8.7 million in Q1 2026, as increased research and development and commercial expenses weighed on margins. (Reuters via Investing.com)

Eli Lilly has opted to end its License and Collaboration Agreement for ocadusertib effective June 15, 2026, removing future milestone and royalty revenues for Rigel and fully transferring development risk for the asset to Rigel. (SEC 8-K Filing)

The R289 IRAK1/4 inhibitor is in Phase 1b dose expansion with topline data only expected by the end of 2026, creating notable execution and outcome uncertainty ahead of key regulatory discussions. (Reuters via Investing.com)

Data summarised monthly by Lightyear AI. Last updated on 21 May 2026.

RIGL News

AllArticlesVideos

Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer

Benzinga·1 month ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

About Rigel Pharmaceuticals, Inc.

Ticker

Employees

RIGL Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

RIGL News

Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer

Buy $RIGL

Upcoming events

No upcoming events

Lightyear

Legal

Work with us

Bulls say / Bears say

Rigel Pharmaceuticals, Inc./$RIGL

About Rigel Pharmaceuticals, Inc.

Ticker

Employees

RIGL Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

RIGL News

Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer

Buy $RIGL

Upcoming events

No upcoming events

What’s the current market cap for Rigel Pharmaceuticals, Inc. stock?

What is the P/E ratio for Rigel Pharmaceuticals, Inc. stock?

Does Rigel Pharmaceuticals, Inc. stock pay dividends?

When is the next Rigel Pharmaceuticals, Inc. dividend payment date?

What is the beta indicator for Rigel Pharmaceuticals, Inc.?

Bulls say / Bears say